The Latest

• 

  Pricing watchdog will take on the rising cost of drugs at launch

  ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from a patient perspective.

  Patient

• 

  First 90 Days

  As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

  Simone Steiner recently joined the French company to set the stage for launch.  

  Biotech

• 

  Trump says ‘very high’ pharmaceutical tariffs coming soon

  While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.

  Commercialization

• 

  Is biopharma dealmaking getting hot again?

  With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.

  Biotech

• 

  The MEK effect on cancer — a slow and steady approach to drug resistance

  Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.

  Biotech

• 

  GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down

  As more drugmakers aim for the lucrative weight loss market, patient challenges linger.

  Commercialization

• 

  Can China sustain a surge in oncology drug innovation?

  The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.

  Biotech

• 

  AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

  The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.

  Biotech

• 

  First 90 Days

  A biopharma bolsters patient centricity and trial diversity goals through newly created role

  Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.

  First 90 Days

• 

  FDA’s new mission to speed drug reviews

  FDA Commissioner Dr. Marty Makary is leading a handful of controversial new initiatives to make the drug review process more streamlined.

  Pharma

• 

  3 of the year’s most notable FDA nods

  The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.

  Commercialization

• 

  Top pharma and biotech conferences in the second half of 2025 and beyond

  Mark your calendars for the most important industry conferences in the second half of 2025 and into next year.

  Updated June 27, 2025

  Biotech

• 

  Biopharma is on edge about NIH funding cuts and what the future holds for research

  Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.

  Biotech

• 

  CDC panel, newly remade by RFK Jr., questions vaccine evidence

  New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.

  Biotech

• 

  After myriad failures, a new wave of ALS drugs approaches

  Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.

  Biotech

• 

  Q&A

  How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

  J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.

  Biotech

• 

  Biogen scores Cannes Festival win with dark humored campaign

  The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

  Commercialization

• 

  Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

  More drugs surpassed $10 billion in revenue last year than ever before.

  Commercialization

• 

  Biotech’s turning point: for every challenge, an opportunity in disguise

  As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.

  Biotech

• 

  Is DTC pharma advertising coming to an end?

  A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.

  Commercialization

• 

  FDA to speed reviews for drugs supporting ‘national interests’

  A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

  Pharma

• 

  How a patient group tackled research diversity for one disease and triggered change for pharma

  A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

  Biotech

• 

  Locked in a federal stalemate, states take PBM reform into their own hands

  Arkansas is leading the nation in banning PBMs from owning pharmacies, as other states advance new restrictions.

  Pharma

• 

  Will pharma finally score a policy win for 340B?

  The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

  Patient

• 

  Profile

  A day in the life of GSK’s U.S. president

  How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.

  Leadership